Page 7 - Immunotech Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

OCALA, Fla., April 10, 2024 AIM ImmunoTech Inc. today announced top-line interim data indicating that combining Ampligen with Keytruda in the treatment of recurrent ovarian cancer may have.

United statesRobert edwardsThomask equelsExchange commissionDepartment of obstetricsImmunotech incGynecologic oncology research at magee womens hospitalUniversity of pittsburgh medical centerGynecology reproductive sciencesImmune checkpoint blockadeRecurrent ovarianPittsburgh medical centerObjective response rateClinical benefit rateProgression free survivalReproductive sciences

Aim ImmunoTech Announces Positive Data From Ampligen Study In Combination With Pembrolizumab

(RTTNews) - Aim ImmunoTech Inc. (AIM) announced positive preliminary findings on Wednesday, showing that pairing Ampligen or rintatolimod with Key.

Thomas equelsImmunotech incObjective response rate

AIM ImmunoTech (AIM) Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech (AIM) Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesThomask equelsRobert edwardsDepartment of obstetricsImmunotech incGynecologic oncology research at magee womens hospitalGynecology reproductive sciencesUniversity of pittsburgh medical centerImmune checkpoint blockadeRecurrent ovarianPittsburgh medical centerObjective response rateClinical benefit rateProgression free survivalReproductive sciencesGynecologic oncology research

AIM ImmunoTech Inc (AMEX:AIM) Q4 2023 Earnings Call Transcript

Operator: Hello. And welcome to the AIM ImmunoTech Fiscal Year 2023 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

United statesChristopher mcaleerJason mccarthyJames molloyChris mcaleerTom equelsThomas equelsImmunotech incDelaware supreme courtPriority developmentExchange commissionMaxim groupEarly access programClinical cancer researchUniversity of pittsburghAlliance global partners

Challenges to Advance Notice Bylaws Are Spiking | Katten Muchin Rosenman LLP

The last three months have seen a jump in shareholder lawsuits challenging “advance notice” provisions in company bylaws. Advance notice provisions are ubiquitous among.

United statesImmunotech incDelaware chancery courtTech incChancellor will